Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) has been given an average recommendation of “Hold” by the five brokerages that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $27.84.
Separately, StockNews.com started coverage on Cara Therapeutics in a research report on Wednesday, January 8th. They issued a “sell” rating for the company.
Check Out Our Latest Report on Cara Therapeutics
Institutional Inflows and Outflows
Cara Therapeutics Stock Up 18.4 %
Shares of NASDAQ:CARA opened at $5.99 on Friday. The firm has a 50 day moving average of $4.28 and a 200 day moving average of $3.95. The company has a market capitalization of $27.37 million, a price-to-earnings ratio of -0.29 and a beta of 0.51. Cara Therapeutics has a 52 week low of $2.71 and a 52 week high of $13.80.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Read More
- Five stocks we like better than Cara Therapeutics
- Investing in Travel Stocks Benefits
- MP Materials: Rare Earth Elements Powering the EV Boom
- 3 Stocks to Consider Buying in October
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- Conference Calls and Individual Investors
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.